Pipeline tracker

What’s in the pipeline

Therapies and technologies tracked by development stage — preclinical, clinical, under review or approved — each with a dated primary source. Nothing is called a breakthrough just because a company announced it.

Development stages, sourced

Selected therapies and technologies at every stage, from preclinical research to approval. Each stage is dated and linked to a primary source.

Casgevy (exagamglogene autotemcel)Vertex Pharmaceuticals and CRISPR Therapeutics · Sickle cell disease and transfusion-dependent beta thalassemia

Approved/cleared · CRISPR/Cas9-edited autologous stem-cell therapyAs of Sep 25, 2026

FDA-approved Dec. 8, 2023 for sickle cell disease (age 12+); CRISPR Therapeutics reported on Aug. 3, 2026 that the FDA extended approval to children 2 years and older.

Intismeran autogene (V940 / mRNA-4157)Moderna and Merck · High-risk resected melanoma (with pembrolizumab)

Phase 3 · Individualized neoantigen mRNA cancer vaccineAs of Sep 25, 2026

Phase 3 INTerpath-001 (NCT05933577) met its primary recurrence-free survival endpoint, announced Aug. 19, 2026; the companies say they will engage regulators on filings (company release).

CTX112 (zugocabtagene geleucel)CRISPR Therapeutics · Autoimmune diseases incl. systemic lupus erythematosus and systemic sclerosis

Phase 1 · Allogeneic CRISPR-edited CD19 CAR-T cell therapyAs of Sep 25, 2026

As of the company's Aug. 3, 2026 update, CTX112 is in Phase 1 basket trials across several autoimmune diseases (company release).

da Vinci 5 surgical system — cardiac indicationsIntuitive Surgical · Cardiac procedures incl. mitral valve repair

Approved/cleared · Robotic-assisted surgical systemAs of Sep 25, 2026

FDA 510(k) clearance for certain cardiac procedures announced Jan. 26, 2026 (company release).

Galleri multi-cancer early detection testGRAIL · Multi-cancer screening in adults 50+

Under review · Cell-free DNA methylation blood test (NGS + machine learning)As of Sep 25, 2026

PMA submitted Jan. 29, 2026; an FDA advisory panel voted 7–2 (one abstention) on Sept. 23, 2026 that benefits outweigh risks, with a final FDA decision pending.

Optive AI software for Swoop portable MRIHyperfine · Point-of-care brain imaging

Approved/cleared · AI image-reconstruction software for portable ultra-low-field MRIAs of Sep 25, 2026

Hyperfine reported FDA clearance of next-generation Optive AI software in its Q2 2026 results on Aug. 6, 2026 (company release).

Hepatocyte epigenetic reprogramming medicineNewLimit · Age-related liver dysfunction

Preclinical · Epigenetic reprogramming therapyAs of Sep 25, 2026

On June 2, 2026 NewLimit said it plans a first human trial of its liver reprogramming medicine in 2027 (company blog).

Stages summarise the most advanced publicly documented status for the named use. “Approved” applies to specific indications and regions only. Nothing here is medical or investment advice.